The growing interest in the therapeutic potential of psychedelics and the decriminalization of natural substances in Massachusetts could positively impact PsyBio Therapeutics' stock price. The company holds a license for synthetic psilocybin, and the collaboration with the University of Cincinnati on non-hallucinogenic substances could lead to new product developments and increased market opportunities.